Title : Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.

Pub. Date : 2006 Apr

PMID : 16633141






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05). Itraconazole cytochrome P450 family 2 subfamily D member 6 Homo sapiens
2 Barnes Akathisia Rating Scale (BARS) of subjects with CYP2D6*10/*10 in the presence of itraconazole pretreatment was significantly higher than that of subjects with CYP2D6*1/*1 genotype in the period of placebo pretreatment. Itraconazole cytochrome P450 family 2 subfamily D member 6 Homo sapiens
3 The moderate effect of CYP2D6*10 genotype on the pharmacokinetics and pharmacodynamics of haloperidol seems to be augmented by the presence of itraconazole pretreatment. Itraconazole cytochrome P450 family 2 subfamily D member 6 Homo sapiens